Perrigo (PRGO)
(Delayed Data from NYSE)
$27.69 USD
-0.49 (-1.74%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $27.72 +0.03 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.69 USD
-0.49 (-1.74%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $27.72 +0.03 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
Zacks News
PRGO vs. PAHC: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PRGO vs. PAHC: Which Stock Is the Better Value Option?
Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results
by Zacks Equity Research
Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.
Perrigo (PRGO) Up 4.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View
by Zacks Equity Research
Perrigo (PRGO) reports mixed third-quarter 2019 results. The Rx segment continues to witness recovery. Stock down.
Perrigo (PRGO) Beats Q3 Earnings Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 11.83% and -0.95%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.
Earnings Preview: Perrigo (PRGO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
Why Is Perrigo (PRGO) Up 6.1% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRGO vs. BIO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PRGO vs. BIO: Which Stock Is the Better Value Option?
Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up
by Zacks Equity Research
Perrigo (PRGO) reports encouraging second-quarter 2019 results. The Rx segment recovers on strong new product sales.
Perrigo (PRGO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 6.17% and 1.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Self Care Americas segment. It remains to be seen if this benefits the company's results in the soon-to-be reported quarter.
Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PRGO or SRDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PRGO vs. SRDX: Which Stock Is the Better Value Option?
Perrigo Completes Ranir Acquisition, Raises '19 Guidance
by Zacks Equity Research
Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.
Why Is Perrigo (PRGO) Down 17.4% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Beats on Q1 Earnings and Sales, Stock Up
by Zacks Equity Research
Perrigo (PRGO) reports encouraging first-quarter 2019 results. The Rx segment recovers during the quarter on strong new product sales.
Perrigo (PRGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 13.83% and 2.20%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?
by Zacks Equity Research
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
Perrigo (PRGO) Down 2.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Q4 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
Perrigo (PRGO) reports wider loss in fourth-quarter 2018. However, sales were marginally higher. Challenges in the Rx segment continues to hurt the top line.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.